Stockholm Uppsala Pharmacometrics (SUP)
Pharmaceutical clinical adventures into pediatrics, or tales of outliers and why F≠1 for intravenous drugs
Per Nydert, Astrid Lindgrens Barnsjukhus
Paediatric posology and the EMA-endorsed graphical dose justification
Rik Schoemaker, Occams
Integrating efficacy and safety biomarkers in a pharmacometric framework to evaluate dosing schedules: a case study of ibrutinib in chronic lymphocytic leukemia
Eman Ibrahim, Uppsala University
Dosing Decoded: A Regulatory View on Drug Labelling
Kristin Karlsson, Medical Products Agency
The impact of MIDD and dose ranging on the zibotentan/dapagliflozin clinical development program
Magnus Åstrand, AstraZeneca
Dose finding in therapeutic areas without available treatments and/or limited predictive biomarker
Emma Boström, Bioarctic
Stockholm Uppsala Pharmacometrics (SUP)